António Araújo, MD, PhD

Principal Investigator

orcid.org/0000-0002-7267-3584

Academic degrees:

PhD in Medical Sciences

Medical Doctor

Positions:

• Head of the Medical Oncology Department at Centro Hospitalar do Porto;

• Invited Full Professor, ICBAS – University of Porto.

Research interests:

• Carcinogenesis biomarkers

• Angiogenesis, namely angiopoietin 2

• Tumoral liquid biopsies

• Development of 2D and 3D tumoral biomimetics platforms
  

Research area keywords:

Cancer, Carcinogenesis, Angiogenesis, Liquid biopsies, Biomimetics platforms

Major Scientific Achievements:

• ScieVessel co-option in NSCLC angiogenesis

• Feasibility of exosomes isolation and characterization in NSCLC patients

• FGFR as a promising target for NSCLC patients.

Selected publications:

1. Coelho AL, Gomes MP, Catarino RJ, Rolfo C, Lopes AM, Medeiros RM, Araujo A. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? Oncotarget 8:39795-39804, 2017.

2. Coelho A, Araujo A, Gomes MP, Catarino RJ, Andrade EB, Lopes AM, Medeiros RM. Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers. Future Oncol 11:3233-3242, 2015.

3. Taverna S, Giallombardo M, Gil-Bazo I, Carreca AP, Castiglia M, Chacártegui J, Araujo A, Alessandro R, Pauwels P, Peeters M, Rolfo C. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget 7:28748-28760, 2016.

4. Tan DS, Araujo A, Zhang J, Signorovitch J, Zhou Z, Cai X, Liu G. Comparative efficacy of ceritinib and crizotinib as initial anaplastic lymphoma kinase-targeted therapies in previously treated advanced or metastatic non-small cell lung cancer: an adjusted comparison to external controls. J Thorac Oncol 11:1550-1557, 2016.

5. Porta R, Borea R, Coelho A, Khan S, Araujo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Crit Rev Oncol Hematol 113:256-267, 2017.

Ongoing projects:

Liquid biopsy as a non-invasive test in urologic cancers.

Lung BioMimic: a 3D biomimetic platform for lung cancer translational studies.

International collaborations:

• Jens Mariano Provencio, MD PhD, Hospital Puerta de Hierro, Research line – liquid biopsy, 3D biomimetic platform

• Christian Rolfo, MD PhD, University Hospital Antwerp, Research line – liquid biopsy.